CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
Celebrex +1 moredrug
Likely dose
Celebrex 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00614406
NCT00614406N/ACompleted
CompareCT.gov

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle.

Oregon Health and Science University·interventional·Posted Feb 13, 2008·Updated Dec 13, 2012

In Brief

A clinical study evaluating Celebrex and Placebo for Ovulation (Follicular Rupture Yes/no) and 2 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The investigators propose to test the hypothesis that the use of a prostaglandin inhibitor will result in premature luteolysis (ovulation failure) in women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days), Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
CountriesUnited States
CollaboratorsSociety of Family Planning

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2008
Enrollment StartJan 1, 2008
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.4 years ago

Interventions

Celebrexdrug

One 400mg tablet daily.

Placebodrug

One tablet daily.